Status:
UNKNOWN
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
Lead Sponsor:
Federal University of Espirito Santo
Collaborating Sponsors:
Secretaria de Estado da Saúde do Espírito Santo - SESA
Centro de Pesquisas René Rachou
Conditions:
COVID-19
Vaccine Adverse Reaction
Eligibility:
All Genders
60+ years
Brief Summary
The objective of this observational case-crossover study is to evaluate the effectiveness, safety and immunogenicity of the second booster dose in the elderly. There are an estimated 490,000 eligible ...
Detailed Description
Faced with the new scenario of high transmission of the Ômicron variant of SARS-COV-2, in which the elderly over 60 years and immunosuppressed even vaccinated with three doses have become a population...
Eligibility Criteria
Inclusion
- Age equal to or greater than 60 years
- Residents of Espírito Santo, Brazil
Exclusion
- Being under active treatment (chemotherapy and/or radiotherapy) for the treatment of any type of neoplasm
- Being admitted to an institutionalization establishment for the elderly (hospitals, nursing homes, shelters or similar).
- Patients with mental illness with inability to understand the consent form
Key Trial Info
Start Date :
March 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
490000 Patients enrolled
Trial Details
Trial ID
NCT05283902
Start Date
March 19 2022
End Date
October 1 2022
Last Update
March 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Valéria Valim
Vitória, Espírito Santo, Brazil, 29041-295